董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey S. Flier | 男 | Director | 75 | 15.63万美元 | 未持股 | 2023-04-24 |
| Michael Gilman | 男 | Director | 68 | 19.92万美元 | 未持股 | 2023-04-24 |
| Joshua Reed | 男 | Director | 50 | 15.47万美元 | 未持股 | 2023-04-24 |
| Kristina Burow | 女 | Director | 49 | 15.69万美元 | 未持股 | 2023-04-24 |
| Srinivas Akkaraju | 男 | Director | 55 | 未披露 | 未持股 | 2023-04-24 |
| Jay Backstrom | 男 | Director and President and Chief Executive Officer | 68 | 707.63万美元 | 未持股 | 2023-04-24 |
| Joshua Reed | 男 | Director | 50 | 未披露 | 未持股 | 2023-04-24 |
| Richard H. Brudnick | 男 | Director | 66 | 未披露 | 未持股 | 2023-04-24 |
| Akshay Vaishnaw | 男 | Director | 60 | 19.82万美元 | 未持股 | 2023-04-24 |
| Srinivas Akkaraju | 男 | Director | 55 | 39.40万美元 | 未持股 | 2023-04-24 |
| David Hallal | 男 | Chairman of the Board | 56 | 31.59万美元 | 未持股 | 2023-04-24 |
| Amir Nashat | 男 | Director | 50 | 14.57万美元 | 未持股 | 2023-04-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jay Backstrom | 男 | Director and President and Chief Executive Officer | 68 | 707.63万美元 | 未持股 | 2023-04-24 |
| Junlin Ho | 女 | General Counsel & Corporate Secretary | 44 | 212.84万美元 | 未持股 | 2023-04-24 |
| Jing Marantz | 女 | Chief Medical Officer | 58 | 未披露 | 未持股 | 2023-04-24 |
| Edward H. Myles | 男 | Chief Operating Officer and Chief Financial Officer | 51 | 310.99万美元 | 未持股 | 2023-04-24 |
| Caryn Parlavecchio | 女 | Chief Human Resources Officer | 51 | 未披露 | 未持股 | 2023-04-24 |
| Mo Qatanani | 男 | Senior Vice President and Head of Research | 49 | 未披露 | 未持股 | 2023-04-24 |
| Tracey Sacco | 女 | Chief Commercial Officer | 46 | 未披露 | 未持股 | 2023-04-24 |
董事简历
中英对照 | 中文 | 英文- Jeffrey S. Flier
-
JeffreyS.Flier自2016年10月以来一直担任我们的董事会成员。自2016年8月以来，Flier博士一直担任Higginson生理学和医学教授以及哈佛大学杰出服务教授，并于2007年至2016年8月担任哈佛大学医学院第二十一任院长。此前，Flier从2002年到2007年担任Beth Israel Deaconess Medical Center首席学术官，并担任Harvard Medical School学术项目教务长。他是美国国家医学科学院的当选成员和美国艺术与科学院院士，他的许多荣誉包括美国糖尿病协会的礼来公司奖，以及美国生理学会的伯森讲座。他曾获得美国糖尿病协会（the American Diabetes Association）的2005年班廷奖章，这是其最高的科学荣誉。Flier博士以最高的学术荣誉获得纽约城市学院（City College of New York）的学士学位和西奈山医学院（Mount Sinai School of Medicine）的医学博士学位，他完成了西奈山医学院（Mount Sinai School of Medicine）的住院医师培训。
Jeffrey S. Flier,has served as a director since October 2016. Since August 2016, Dr. Flier has served as the Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor, and from 2007 to August 2016 served as the twenty-first Dean of the Faculty of Medicine at Harvard University. Previously, from 2002 to 2007, Dr. Flier served as Chief Academic Officer of Beth Israel Deaconess Medical Center and served as Harvard Medical School Faculty Dean for Academic Programs. An elected member of the National Academy of Medicine and a fellow of the American Academy of Arts and Sciences, his many honors include the Eli Lilly Award of the American Diabetes Association, and the Berson Lecture of the American Physiological Society. He was the recipient of the 2005 Banting Medal from the American Diabetes Association, its highest scientific honor. Dr. Flier received his B.S. from City College of New York and his M.D. from Mount Sinai School of Medicine with highest academic honors, and he completed his residency training at Mount Sinai School of Medicine. - JeffreyS.Flier自2016年10月以来一直担任我们的董事会成员。自2016年8月以来，Flier博士一直担任Higginson生理学和医学教授以及哈佛大学杰出服务教授，并于2007年至2016年8月担任哈佛大学医学院第二十一任院长。此前，Flier从2002年到2007年担任Beth Israel Deaconess Medical Center首席学术官，并担任Harvard Medical School学术项目教务长。他是美国国家医学科学院的当选成员和美国艺术与科学院院士，他的许多荣誉包括美国糖尿病协会的礼来公司奖，以及美国生理学会的伯森讲座。他曾获得美国糖尿病协会（the American Diabetes Association）的2005年班廷奖章，这是其最高的科学荣誉。Flier博士以最高的学术荣誉获得纽约城市学院（City College of New York）的学士学位和西奈山医学院（Mount Sinai School of Medicine）的医学博士学位，他完成了西奈山医学院（Mount Sinai School of Medicine）的住院医师培训。
- Jeffrey S. Flier,has served as a director since October 2016. Since August 2016, Dr. Flier has served as the Higginson Professor of Physiology and Medicine and Harvard University Distinguished Service Professor, and from 2007 to August 2016 served as the twenty-first Dean of the Faculty of Medicine at Harvard University. Previously, from 2002 to 2007, Dr. Flier served as Chief Academic Officer of Beth Israel Deaconess Medical Center and served as Harvard Medical School Faculty Dean for Academic Programs. An elected member of the National Academy of Medicine and a fellow of the American Academy of Arts and Sciences, his many honors include the Eli Lilly Award of the American Diabetes Association, and the Berson Lecture of the American Physiological Society. He was the recipient of the 2005 Banting Medal from the American Diabetes Association, its highest scientific honor. Dr. Flier received his B.S. from City College of New York and his M.D. from Mount Sinai School of Medicine with highest academic honors, and he completed his residency training at Mount Sinai School of Medicine.
- Michael Gilman
-
Michael Gilman自2013年11月以来一直担任我们的董事会成员。吉尔曼博士目前是Arrakis Therapeutics，Inc.的董事长兼首席执行官，他自2016年起担任该职位，并自2016年起担任Obsidian Therapeutics，Inc.的首席执行官兼董事。此前，Gilman博士于2014年至2016年担任Padlock Therapeutics，Inc.的创始人兼首席执行官。在加入Padlock之前，Gilman博士从2012年到2013年在Biogen Idec Inc.担任高级副总裁，早期管道。他于2012年加入Biogen Idec Inc.（收购Stromedix，Inc.），在那里他曾担任创始人兼首席执行官。在2006年创立Stromedix之前，从1999年到2005年，Gilman博士担任过各种职务，最近担任Biogen Idec的研究执行Vice President。从1994年到1999年，吉尔曼博士在ARIADPharmaceuticals，Inc.担任执行Vice President和首席科学官。Gilman从1986年到1994年担任纽约Cold Spring Harbor Laboratory科学人员。他也任职于X4Pharmaceuticals，Inc.的董事会和以色列生物技术加速器Futurx的科学顾问委员会。吉尔曼博士是怀特黑德研究所罗伯特·温伯格博士的博士后。他持有加州大学伯克利分校（University of California，Berkeley）的生物化学博士学位，以及麻省理工学院（Massachusetts Institute of Technology）的生命科学学士学位。
Michael Gilman,has served as a director since November 2013. Mr. Gilman is currently Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016. From October 2016 to April 2019, Mr. Gilman was Chief Executive Officer for Obsidian Therapeutics, Inc. Previously, from 2014 to 2016, Mr. Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Mr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Mr. Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Mr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Mr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of Arrakis Therapeutics, Inc., Obsidian Therapeutics, Inc. and Novartis Venture Fund, and on the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. He previously served on the Board of Directors of X4 Pharmaceuticals, Inc. from September 2014 to March 2019. Mr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology. - Michael Gilman自2013年11月以来一直担任我们的董事会成员。吉尔曼博士目前是Arrakis Therapeutics，Inc.的董事长兼首席执行官，他自2016年起担任该职位，并自2016年起担任Obsidian Therapeutics，Inc.的首席执行官兼董事。此前，Gilman博士于2014年至2016年担任Padlock Therapeutics，Inc.的创始人兼首席执行官。在加入Padlock之前，Gilman博士从2012年到2013年在Biogen Idec Inc.担任高级副总裁，早期管道。他于2012年加入Biogen Idec Inc.（收购Stromedix，Inc.），在那里他曾担任创始人兼首席执行官。在2006年创立Stromedix之前，从1999年到2005年，Gilman博士担任过各种职务，最近担任Biogen Idec的研究执行Vice President。从1994年到1999年，吉尔曼博士在ARIADPharmaceuticals，Inc.担任执行Vice President和首席科学官。Gilman从1986年到1994年担任纽约Cold Spring Harbor Laboratory科学人员。他也任职于X4Pharmaceuticals，Inc.的董事会和以色列生物技术加速器Futurx的科学顾问委员会。吉尔曼博士是怀特黑德研究所罗伯特·温伯格博士的博士后。他持有加州大学伯克利分校（University of California，Berkeley）的生物化学博士学位，以及麻省理工学院（Massachusetts Institute of Technology）的生命科学学士学位。
- Michael Gilman,has served as a director since November 2013. Mr. Gilman is currently Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016. From October 2016 to April 2019, Mr. Gilman was Chief Executive Officer for Obsidian Therapeutics, Inc. Previously, from 2014 to 2016, Mr. Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Mr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Mr. Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Mr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Mr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of Arrakis Therapeutics, Inc., Obsidian Therapeutics, Inc. and Novartis Venture Fund, and on the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. He previously served on the Board of Directors of X4 Pharmaceuticals, Inc. from September 2014 to March 2019. Mr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.
- Joshua Reed
-
Joshua Reed，工商管理硕士，自2018年7月起担任我们的首席财务官。在加入Aldeyra之前，里德曾于2016年6月至2018年7月担任百时美施贵宝（Bristol-Myers Squibb’；s）美国和波多黎各业务的Vice President兼财务主管，2013年9月至2016年6月，该业务规模达120亿美元，里德曾担任执行董事，在此之前，Reed先生在BMS担任越来越重要的职务，包括财务规划和分析，供应链金融，运营金融以及并购方面的职位。在此之前，里德先生是摩根大通（JPMorgan Chase）负责战略业务发展的Vice President，并在瑞士信贷第一波士顿银行（Credit Suisse First Boston）担任投资银行职位，在那里他专注于并购。Reed先生在罗格斯大学（Rutgers University）获得金融学学士学位，并在密歇根大学罗斯商学院（University of Michigan&8217；s Ross School of Business）获得金融与企业战略方向的工商管理硕士学位。
Joshua Reed,has served as a director since March 2021. Mr. Reed is currently Chief Financial Officer of Omega Therapeutics, a role he has served in since May 2022. From July 2018 until May 2022, Mr. Reed served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb's (BMS) United States and Puerto Rico operations, a $12 billion business unit. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan's Ross School of Business. - Joshua Reed，工商管理硕士，自2018年7月起担任我们的首席财务官。在加入Aldeyra之前，里德曾于2016年6月至2018年7月担任百时美施贵宝（Bristol-Myers Squibb’；s）美国和波多黎各业务的Vice President兼财务主管，2013年9月至2016年6月，该业务规模达120亿美元，里德曾担任执行董事，在此之前，Reed先生在BMS担任越来越重要的职务，包括财务规划和分析，供应链金融，运营金融以及并购方面的职位。在此之前，里德先生是摩根大通（JPMorgan Chase）负责战略业务发展的Vice President，并在瑞士信贷第一波士顿银行（Credit Suisse First Boston）担任投资银行职位，在那里他专注于并购。Reed先生在罗格斯大学（Rutgers University）获得金融学学士学位，并在密歇根大学罗斯商学院（University of Michigan&8217；s Ross School of Business）获得金融与企业战略方向的工商管理硕士学位。
- Joshua Reed,has served as a director since March 2021. Mr. Reed is currently Chief Financial Officer of Omega Therapeutics, a role he has served in since May 2022. From July 2018 until May 2022, Mr. Reed served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb's (BMS) United States and Puerto Rico operations, a $12 billion business unit. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan's Ross School of Business.
- Kristina Burow
-
Kristina Burow，自2020年1月起担任Neumora Therapeutics公司董事会成员。自2011年11月以来，Burow女士一直担任ARCH Venture Partners的董事总经理，该公司是一家专注于早期技术公司的风险投资公司，之前曾于2002年至2011年在ARCH担任过各种职务。Burow女士是私营生物技术公司Orbital Therapeutics的联合创始人，自2022年4月起担任该公司董事会成员。她目前担任多家私营生物技术公司的董事会成员，包括自2018年2月起的Boundless Bio和自2017年2月起的Autobahn Therapeutics，以及多家上市生物技术公司的董事会成员，包括自2017年6月起的Beam Therapeutics和自2014年起的Scholar Rock。她曾是被Celgene收购的上市生物技术公司Receptos, Inc.的联合创始人和董事会成员，以及私营能源公司Sapphire Energy的联合创始人和董事会成员。Burow女士曾担任多家公共生物技术和生物制药公司的董事会成员，包括2018年1月至2023年9月的Gossamer Bio、2013年至2022年3月的UNITY Biotechnology，Inc.、2015年5月至2022年2月的Metacrine、2015年至2019年12月的Sienna Biopharmaceuticals，以及2017年1月至2020年9月的Vir Biotechnology，以及多家私营生物技术和生物制药公司，包括2017年1月至2021年10月的Vividion Therapeutics，2012年至2021年10月的AgBiome，LLC，2013年至2020年9月的BlackThorn，以及2009年至2020年的Lycera。在加入ARCH之前，Burow女士是诺华生物风险基金的合伙人，也是诺华研究基金会基因组学研究所的早期雇员，这两家机构都隶属于上市制药公司诺华。Burow女士拥有加州大学伯克利分校的化学学士学位、哥伦比亚大学的化学硕士学位和芝加哥大学布斯商学院的工商管理硕士学位。
Kristina Burow,has served as a member of Boundless Bio, Inc. board of directors since June 2019. Ms. Burow has served as a Managing Director of ARCH Venture Partners, a venture capital firm, since November 2011 and previously held positions of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow currently serves on the board of directors of several biopharmaceutical and biotechnology companies, including: Beam Therapeutics Inc., a publicly traded biotechnology company; Scholar Rock Holding Corporation, a publicly traded biopharmaceutical company; Autobahn Therapeutics, Inc., a privately held biopharmaceutical company; ROME Therapeutics, Inc., a privately held biopharmaceutical company; Asteroid Therapeutics, Inc., a privately held biopharmaceutical company; Metsera Therapeutics, Inc., a privately held biopharmaceutical company; Treeline Therapeutics Inc., a privately held biopharmaceutical company; and Pretzel Therapeutics, Inc., a privately held biopharmaceutical company. Ms. Burow is a co-founder and director of Neumora Therapeutics, Inc., a publicly traded biopharmaceutical company and Orbital Therapeutics Inc., a privately held biotechnology company. Ms. Burow previously was a co-founder and member of the board of directors of Receptos Inc., a publicly traded pharmaceutical company, until its acquisition by Celgene Corporation, a global biopharmaceutical company, and of Sapphire Energy, Inc., an energy company. Ms. Burow previously served as a member of the board of directors of Boragen, Inc., a privately held biotechnology company; Gossamer Bio, Inc., a publicly traded biopharmaceutical company; Unity Biotechnology, Inc., a publicly traded biopharmaceutical company; AgBiome Inc., a privately held biotechnology company; Metacrine, Inc., a publicly traded pharmaceutical company; Vir Biotechnology Inc., a publicly traded biotechnology company; BlackThorn Therapeutics, Inc., a privately held biopharmaceutical company; Sienna Biopharmaceuticals, Inc.; a publicly traded biopharmaceutical company; and Epirium Bio, a privately held pharmaceutical company. Ms. Burow has participated in a number of other ARCH portfolio companies including: Erasca, Inc.; Dewpoint Therapeutics, Inc.; Aledade, Inc.; Kythera Biopharmaceuticals, Inc.; Mindstrong Inc.; Kura Oncology, Inc.; and Ikaria, Inc., acquired by Madison Dearborn Partners, a private equity firm. Prior to joining ARCH, Ms. Burow served as an associate with the Novartis BioVenture Fund and was an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow received a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University, and an M.B.A. from the University of Chicago. Ms. Burow's extensive experience serving on the board of directors of clinical-stage biotechnology companies and her investment experience in the life sciences industry contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc. - Kristina Burow，自2020年1月起担任Neumora Therapeutics公司董事会成员。自2011年11月以来，Burow女士一直担任ARCH Venture Partners的董事总经理，该公司是一家专注于早期技术公司的风险投资公司，之前曾于2002年至2011年在ARCH担任过各种职务。Burow女士是私营生物技术公司Orbital Therapeutics的联合创始人，自2022年4月起担任该公司董事会成员。她目前担任多家私营生物技术公司的董事会成员，包括自2018年2月起的Boundless Bio和自2017年2月起的Autobahn Therapeutics，以及多家上市生物技术公司的董事会成员，包括自2017年6月起的Beam Therapeutics和自2014年起的Scholar Rock。她曾是被Celgene收购的上市生物技术公司Receptos, Inc.的联合创始人和董事会成员，以及私营能源公司Sapphire Energy的联合创始人和董事会成员。Burow女士曾担任多家公共生物技术和生物制药公司的董事会成员，包括2018年1月至2023年9月的Gossamer Bio、2013年至2022年3月的UNITY Biotechnology，Inc.、2015年5月至2022年2月的Metacrine、2015年至2019年12月的Sienna Biopharmaceuticals，以及2017年1月至2020年9月的Vir Biotechnology，以及多家私营生物技术和生物制药公司，包括2017年1月至2021年10月的Vividion Therapeutics，2012年至2021年10月的AgBiome，LLC，2013年至2020年9月的BlackThorn，以及2009年至2020年的Lycera。在加入ARCH之前，Burow女士是诺华生物风险基金的合伙人，也是诺华研究基金会基因组学研究所的早期雇员，这两家机构都隶属于上市制药公司诺华。Burow女士拥有加州大学伯克利分校的化学学士学位、哥伦比亚大学的化学硕士学位和芝加哥大学布斯商学院的工商管理硕士学位。
- Kristina Burow,has served as a member of Boundless Bio, Inc. board of directors since June 2019. Ms. Burow has served as a Managing Director of ARCH Venture Partners, a venture capital firm, since November 2011 and previously held positions of increasing responsibility at ARCH from August 2002 to November 2011. Ms. Burow currently serves on the board of directors of several biopharmaceutical and biotechnology companies, including: Beam Therapeutics Inc., a publicly traded biotechnology company; Scholar Rock Holding Corporation, a publicly traded biopharmaceutical company; Autobahn Therapeutics, Inc., a privately held biopharmaceutical company; ROME Therapeutics, Inc., a privately held biopharmaceutical company; Asteroid Therapeutics, Inc., a privately held biopharmaceutical company; Metsera Therapeutics, Inc., a privately held biopharmaceutical company; Treeline Therapeutics Inc., a privately held biopharmaceutical company; and Pretzel Therapeutics, Inc., a privately held biopharmaceutical company. Ms. Burow is a co-founder and director of Neumora Therapeutics, Inc., a publicly traded biopharmaceutical company and Orbital Therapeutics Inc., a privately held biotechnology company. Ms. Burow previously was a co-founder and member of the board of directors of Receptos Inc., a publicly traded pharmaceutical company, until its acquisition by Celgene Corporation, a global biopharmaceutical company, and of Sapphire Energy, Inc., an energy company. Ms. Burow previously served as a member of the board of directors of Boragen, Inc., a privately held biotechnology company; Gossamer Bio, Inc., a publicly traded biopharmaceutical company; Unity Biotechnology, Inc., a publicly traded biopharmaceutical company; AgBiome Inc., a privately held biotechnology company; Metacrine, Inc., a publicly traded pharmaceutical company; Vir Biotechnology Inc., a publicly traded biotechnology company; BlackThorn Therapeutics, Inc., a privately held biopharmaceutical company; Sienna Biopharmaceuticals, Inc.; a publicly traded biopharmaceutical company; and Epirium Bio, a privately held pharmaceutical company. Ms. Burow has participated in a number of other ARCH portfolio companies including: Erasca, Inc.; Dewpoint Therapeutics, Inc.; Aledade, Inc.; Kythera Biopharmaceuticals, Inc.; Mindstrong Inc.; Kura Oncology, Inc.; and Ikaria, Inc., acquired by Madison Dearborn Partners, a private equity firm. Prior to joining ARCH, Ms. Burow served as an associate with the Novartis BioVenture Fund and was an early employee at the Genomics Institute of the Novartis Research Foundation. Ms. Burow received a B.S. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University, and an M.B.A. from the University of Chicago. Ms. Burow's extensive experience serving on the board of directors of clinical-stage biotechnology companies and her investment experience in the life sciences industry contributed to Boundless Bio, Inc. board of directors' conclusion that she should serve as a director of Boundless Bio, Inc.
- Srinivas Akkaraju
-
Srinivas Akkaraju，自2022年7月起担任董事。Akkaraju博士是Samsara BioCapital的创始人和管理普通合伙人。此前，2013年4月至2016年2月，担任Sofinnova Ventures普通合伙人。2009年1月至2013年4月，任新叶创投董事总经理。此前，他在私募股权公司Panorama Capital，LLC担任董事总经理。在共同创立Panorama Capital之前，他曾任职于J.P. Morgan Partners，他于2001年加入该公司，并于2005年成为该公司的合伙人。1998年10月至2001年4月，他在一家生物技术公司基因泰克（现在是罗氏集团的全资成员）从事业务和企业发展工作，最近担任高级经理。在加入基因泰克之前，Akkaraju博士是斯坦福大学的一名研究生，在那里他获得了医学博士和免疫学博士学位。他在莱斯大学获得了生物化学和计算机科学的本科学位。Akkaraju博士还担任Chinook Therapeutics、Intercept制药、Mineralys Therapeutics和Syros医药的董事。此前，Akkaraju博士曾在Seattle Genetics、Barrier Therapeutics、Eyetech Pharmaceuticals、ZS Pharma、Synageva Biopharma Corp. BioPharma Corp.、Jiya Acquisition Corp.、aTyr制药、阿玛琳 Corporation PLC的董事会担任董事。
Srinivas Akkaraju,has served as a director since July 2022. Dr. Akkaraju is a Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, he was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Dr. Akkaraju also serves as a director of Chinook Therapeutics, Intercept Pharmaceuticals, Mineralys Therapeutics, and Syros Pharmaceuticals. Previously, Dr. Akkaraju served as a director on the boards of Seattle Genetics, Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp., Jiya Acquisition Corp., aTyr Pharma, and Amarin Corporation plc. - Srinivas Akkaraju，自2022年7月起担任董事。Akkaraju博士是Samsara BioCapital的创始人和管理普通合伙人。此前，2013年4月至2016年2月，担任Sofinnova Ventures普通合伙人。2009年1月至2013年4月，任新叶创投董事总经理。此前，他在私募股权公司Panorama Capital，LLC担任董事总经理。在共同创立Panorama Capital之前，他曾任职于J.P. Morgan Partners，他于2001年加入该公司，并于2005年成为该公司的合伙人。1998年10月至2001年4月，他在一家生物技术公司基因泰克（现在是罗氏集团的全资成员）从事业务和企业发展工作，最近担任高级经理。在加入基因泰克之前，Akkaraju博士是斯坦福大学的一名研究生，在那里他获得了医学博士和免疫学博士学位。他在莱斯大学获得了生物化学和计算机科学的本科学位。Akkaraju博士还担任Chinook Therapeutics、Intercept制药、Mineralys Therapeutics和Syros医药的董事。此前，Akkaraju博士曾在Seattle Genetics、Barrier Therapeutics、Eyetech Pharmaceuticals、ZS Pharma、Synageva Biopharma Corp. BioPharma Corp.、Jiya Acquisition Corp.、aTyr制药、阿玛琳 Corporation PLC的董事会担任董事。
- Srinivas Akkaraju,has served as a director since July 2022. Dr. Akkaraju is a Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, he was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Dr. Akkaraju also serves as a director of Chinook Therapeutics, Intercept Pharmaceuticals, Mineralys Therapeutics, and Syros Pharmaceuticals. Previously, Dr. Akkaraju served as a director on the boards of Seattle Genetics, Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp., Jiya Acquisition Corp., aTyr Pharma, and Amarin Corporation plc.
- Jay Backstrom
-
Jay Backstrom，自2022年9月起担任董事兼Scholar Rock Holding Corporation总裁兼首席执行官。在加入Scholar Rock之前，从2019年12月到2021年12月，Backstrom博士在Acceleron制药担任研发执行副总裁，该公司于2021年被默沙东收购。Backstrom博士此前于2016年4月至2019年12月担任新基医药公司的首席医疗官，此前曾于2008年3月至2016年3月在Celgene担任其他职务。2002年至2008年，Backstrom博士在Pharmion Corporation工作，先是担任北美医疗事务和安全主管，后来担任全球医疗和安全副总裁。在加入Pharmion之前，Backstrom博士还曾在Quintiles Corporation、Hoechst Marion Roussel，Inc.和Marion Merrell Dow，Inc.任职。Backstrom博士目前是LAVA Therapeutics N.V.、Be BioPharma，Inc.和Disc Medicine，Inc.（他将于2023年6月卸任）的董事会成员。Backstrom博士在天普大学医学院获得医学博士学位，并拥有圣路易斯大学公共卫生学院的硕士学位。
Jay Backstrom,has served as a director and Scholar Rock Holding Corporation President and Chief Executive Officer since September 2022. Prior to joining Scholar Rock, from December 2019 to December 2021, Dr. Backstrom served as Executive Vice President, Research and Development at Acceleron Pharma, which was acquired by Merck in 2021. Dr. Backstrom previously served as Chief Medical Officer of Celgene Corporation from April 2016 to December 2019, having served in other roles at Celgene from March 2008 to March 2016. From 2002 to 2008 Dr. Backstrom worked at Pharmion Corporation, serving first as the Head of North American Medical Affairs and Safety and later as Vice President, Global Medical and Safety. Prior to Pharmion, Dr. Backstrom also held roles at Quintiles Corporation, Hoechst Marion Roussel, Inc. and Marion Merrell Dow, Inc. Dr. Backstrom currently sits on the board of directors of Lava Therapeutics N.V., Be BioPharma, Inc., and Disc Medicine, Inc. (which he will be stepping down from in June 2023). Dr. Backstrom earned his M.D. from Temple University School of Medicine, and holds an M.P.H. From St. Louis University School of Public Health. - Jay Backstrom，自2022年9月起担任董事兼Scholar Rock Holding Corporation总裁兼首席执行官。在加入Scholar Rock之前，从2019年12月到2021年12月，Backstrom博士在Acceleron制药担任研发执行副总裁，该公司于2021年被默沙东收购。Backstrom博士此前于2016年4月至2019年12月担任新基医药公司的首席医疗官，此前曾于2008年3月至2016年3月在Celgene担任其他职务。2002年至2008年，Backstrom博士在Pharmion Corporation工作，先是担任北美医疗事务和安全主管，后来担任全球医疗和安全副总裁。在加入Pharmion之前，Backstrom博士还曾在Quintiles Corporation、Hoechst Marion Roussel，Inc.和Marion Merrell Dow，Inc.任职。Backstrom博士目前是LAVA Therapeutics N.V.、Be BioPharma，Inc.和Disc Medicine，Inc.（他将于2023年6月卸任）的董事会成员。Backstrom博士在天普大学医学院获得医学博士学位，并拥有圣路易斯大学公共卫生学院的硕士学位。
- Jay Backstrom,has served as a director and Scholar Rock Holding Corporation President and Chief Executive Officer since September 2022. Prior to joining Scholar Rock, from December 2019 to December 2021, Dr. Backstrom served as Executive Vice President, Research and Development at Acceleron Pharma, which was acquired by Merck in 2021. Dr. Backstrom previously served as Chief Medical Officer of Celgene Corporation from April 2016 to December 2019, having served in other roles at Celgene from March 2008 to March 2016. From 2002 to 2008 Dr. Backstrom worked at Pharmion Corporation, serving first as the Head of North American Medical Affairs and Safety and later as Vice President, Global Medical and Safety. Prior to Pharmion, Dr. Backstrom also held roles at Quintiles Corporation, Hoechst Marion Roussel, Inc. and Marion Merrell Dow, Inc. Dr. Backstrom currently sits on the board of directors of Lava Therapeutics N.V., Be BioPharma, Inc., and Disc Medicine, Inc. (which he will be stepping down from in June 2023). Dr. Backstrom earned his M.D. from Temple University School of Medicine, and holds an M.P.H. From St. Louis University School of Public Health.
- Joshua Reed
-
Joshua Reed，自2021年3月起担任董事。Reed先生目前是Omega Therapeutics的首席财务官，自2022年5月起担任该职务。2018年7月至2022年5月，Reed先生在Aldeyra Therapeutics担任首席财务官，负责财务、业务发展、投资者关系、合规、人力资源和信息技术。在加入Aldeyra之前，2016年6月至2018年7月，Reed先生曾担任百时美施贵宝（BMS）美国和波多黎各业务的副总裁兼财务主管，这是一个价值120亿美元的业务部门。在此之前，Reed先生在BMS担任过越来越多的职责，包括财务规划和分析、供应链金融、运营金融以及并购方面的职位。在此之前，Reed先生在摩根大通担任战略业务发展副总裁，并在瑞士信贷第一波士顿担任投资银行职务，专注于并购业务。Reed先生在罗格斯大学获得金融学士学位，在密歇根大学罗斯商学院获得金融和企业战略专业的工商管理硕士学位。
Joshua Reed,has served as a director since March 2021. Mr. Reed is currently Chief Financial Officer of Omega Therapeutics, a role he has served in since May 2022. From July 2018 until May 2022, Mr. Reed served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb's (BMS) United States and Puerto Rico operations, a $12 billion business unit. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan's Ross School of Business. - Joshua Reed，自2021年3月起担任董事。Reed先生目前是Omega Therapeutics的首席财务官，自2022年5月起担任该职务。2018年7月至2022年5月，Reed先生在Aldeyra Therapeutics担任首席财务官，负责财务、业务发展、投资者关系、合规、人力资源和信息技术。在加入Aldeyra之前，2016年6月至2018年7月，Reed先生曾担任百时美施贵宝（BMS）美国和波多黎各业务的副总裁兼财务主管，这是一个价值120亿美元的业务部门。在此之前，Reed先生在BMS担任过越来越多的职责，包括财务规划和分析、供应链金融、运营金融以及并购方面的职位。在此之前，Reed先生在摩根大通担任战略业务发展副总裁，并在瑞士信贷第一波士顿担任投资银行职务，专注于并购业务。Reed先生在罗格斯大学获得金融学士学位，在密歇根大学罗斯商学院获得金融和企业战略专业的工商管理硕士学位。
- Joshua Reed,has served as a director since March 2021. Mr. Reed is currently Chief Financial Officer of Omega Therapeutics, a role he has served in since May 2022. From July 2018 until May 2022, Mr. Reed served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. Prior to joining Aldeyra, from June 2016 to July 2018, Mr. Reed served as Vice President and Head of Finance for Bristol-Myers Squibb's (BMS) United States and Puerto Rico operations, a $12 billion business unit. Prior to that, Mr. Reed held roles of increasing responsibility at BMS, including positions in financial planning and analysis, supply chain finance, operations finance, and mergers and acquisitions. Prior to that, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed received a B.S. in Finance from Rutgers University and an M.B.A. with concentrations in Finance and Corporate Strategy from the University of Michigan's Ross School of Business.
- Richard H. Brudnick
-
Richard H. Brudnick，自2023年4月起担任董事。Brudnick先生于2022年7月加入Prime Medicine公司，现任首席商务官。在2018年6月至2022年6月加入Prime Medicine之前，Brudnick先生担任Codiak BioSciences公司首席业务官兼战略主管。2016年5月至2018年3月，Brudnick先生担任Bioverativ，Inc.业务发展和联盟管理执行副总裁，Brudnick先生于2014年8月至2016年5月担任渤健公司企业发展高级副总裁。Brudnick先生于2001年加入渤健，曾在投资组合战略与业务发展以及企业发展领域担任高级职务。在加入渤健之前，布鲁德尼克先生是一家区域医药分销商的首席执行官，也是贝恩公司的战略顾问。布鲁德尼克先生获得了麻省理工学院管理科学学士和硕士学位。Brudnick先生是Tamarix Pharma Ltd.、Volition RX Limited（他将于2023年5月卸任）和InflaRx N.V.的董事会成员。
Richard H. Brudnick,has served as a director since April 2023. Mr. Brudnick joined Prime Medicine Inc. in July 2022, and currently serves as Chief Business Officer. Prior to joining Prime Medicine from June 2018 to June 2022, Mr. Brudnick was Chief Business Officer and Head of Strategy for Codiak BioSciences, Inc. From May 2016 to March 2018, Mr. Brudnick was Executive Vice President of Business Development and Alliance Management at Bioverativ, Inc., and Mr. Brudnick served as Biogen's Senior Vice President of Corporate Development from August 2014 until May 2016. Mr. Brudnick joined Biogen in 2001 and held senior positions in the areas of Portfolio Strategy & Business Development and Corporate Development. Before joining Biogen, Mr. Brudnick was the Chief Executive Officer of a regional pharmaceutical distributor and a strategy consultant at Bain & Company. Mr. Brudnick received a B.S. and M.S. in Management Science from the Massachusetts Institute of Technology. Mr. Brudnick is a member of the Board of Directors for Tamarix Pharma Ltd.., Volition Rx Limited (which he will be stepping down from in May 2023), and InflaRx N.V. - Richard H. Brudnick，自2023年4月起担任董事。Brudnick先生于2022年7月加入Prime Medicine公司，现任首席商务官。在2018年6月至2022年6月加入Prime Medicine之前，Brudnick先生担任Codiak BioSciences公司首席业务官兼战略主管。2016年5月至2018年3月，Brudnick先生担任Bioverativ，Inc.业务发展和联盟管理执行副总裁，Brudnick先生于2014年8月至2016年5月担任渤健公司企业发展高级副总裁。Brudnick先生于2001年加入渤健，曾在投资组合战略与业务发展以及企业发展领域担任高级职务。在加入渤健之前，布鲁德尼克先生是一家区域医药分销商的首席执行官，也是贝恩公司的战略顾问。布鲁德尼克先生获得了麻省理工学院管理科学学士和硕士学位。Brudnick先生是Tamarix Pharma Ltd.、Volition RX Limited（他将于2023年5月卸任）和InflaRx N.V.的董事会成员。
- Richard H. Brudnick,has served as a director since April 2023. Mr. Brudnick joined Prime Medicine Inc. in July 2022, and currently serves as Chief Business Officer. Prior to joining Prime Medicine from June 2018 to June 2022, Mr. Brudnick was Chief Business Officer and Head of Strategy for Codiak BioSciences, Inc. From May 2016 to March 2018, Mr. Brudnick was Executive Vice President of Business Development and Alliance Management at Bioverativ, Inc., and Mr. Brudnick served as Biogen's Senior Vice President of Corporate Development from August 2014 until May 2016. Mr. Brudnick joined Biogen in 2001 and held senior positions in the areas of Portfolio Strategy & Business Development and Corporate Development. Before joining Biogen, Mr. Brudnick was the Chief Executive Officer of a regional pharmaceutical distributor and a strategy consultant at Bain & Company. Mr. Brudnick received a B.S. and M.S. in Management Science from the Massachusetts Institute of Technology. Mr. Brudnick is a member of the Board of Directors for Tamarix Pharma Ltd.., Volition Rx Limited (which he will be stepping down from in May 2023), and InflaRx N.V.
- Akshay Vaishnaw
-
Akshay Vaishnaw，自2019年5月起担任董事。Vaishnaw博士于2006年加入阿尔尼拉姆制药，现任总裁。在2006年之前，Vaishnaw博士是渤健转化医学高级总监。他在英国威尔士大学医学院获得医学博士学位，在英国伦敦大学获得分子免疫学博士学位。他是英国皇家内科医学院的院士。Vaishnaw博士是Editas Medicine公司的董事会成员，他曾于2014年至2018年担任Visterra公司的董事会成员，之后该公司被出售给大冢制药。
Akshay Vaishnaw,has served as a director since May 2019. Dr. Vaishnaw joined Alnylam Pharmaceuticals in 2006, and currently serves as President. Prior to 2006, Dr. Vaishnaw was Senior Director, Translational Medicine at Biogen. He received his M.D. from the University of Wales College of Medicine, U.K., and his Ph.D. from the University of London, U.K., in molecular immunology. He is a Fellow of the Royal College of Physicians, U.K. Dr. Vaishnaw is a member of the Board of Directors for Editas Medicine Inc. and he served as a Board member of Visterra Inc from 2014 to 2018, before its sale to Otsuka Pharmaceuticals. - Akshay Vaishnaw，自2019年5月起担任董事。Vaishnaw博士于2006年加入阿尔尼拉姆制药，现任总裁。在2006年之前，Vaishnaw博士是渤健转化医学高级总监。他在英国威尔士大学医学院获得医学博士学位，在英国伦敦大学获得分子免疫学博士学位。他是英国皇家内科医学院的院士。Vaishnaw博士是Editas Medicine公司的董事会成员，他曾于2014年至2018年担任Visterra公司的董事会成员，之后该公司被出售给大冢制药。
- Akshay Vaishnaw,has served as a director since May 2019. Dr. Vaishnaw joined Alnylam Pharmaceuticals in 2006, and currently serves as President. Prior to 2006, Dr. Vaishnaw was Senior Director, Translational Medicine at Biogen. He received his M.D. from the University of Wales College of Medicine, U.K., and his Ph.D. from the University of London, U.K., in molecular immunology. He is a Fellow of the Royal College of Physicians, U.K. Dr. Vaishnaw is a member of the Board of Directors for Editas Medicine Inc. and he served as a Board member of Visterra Inc from 2014 to 2018, before its sale to Otsuka Pharmaceuticals.
- Srinivas Akkaraju
-
Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
Srinivas Akkaraju,has served as a member of Alumis Inc. board of directors since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., and Syros Pharmaceuticals, Inc., and numerous private biopharmaceutical companies. During the past five years, he served as a director of Chinook Therapeutics, Inc., Jiya Acquisition Corp., Aravive, Inc. (formerly Versartis, Inc.), Intercept Pharmaceuticals, Inc., Principia Biopharma Inc., and Seattle Genetics, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University. - Srinivas Akkaraju，医学博士、哲学博士。他2003年7月起担任公司董事。2013年4月起，他是Sofinnova Ventures的普通合伙人。2009年1月至2013年4月，他是New Leaf Venture Partners的常务董事。2006年8月至2008年12月，他是私募股权公司Panorama Capital, LLC的常务董事，该公司由JPMorgan Chase & Co.旗下的私募股权部J.P. Morgan Partners, LLC的前风险投资团队创立。Panorama Capital曾建议J.P. Morgan Partners投资Seattle Genetics。共同创立Panorama Capital前，他2001年4月加入J.P. Morgan Partners，2005年1月成为其合伙人。1998年10月至2001年4月，他在Genentech, Inc.业务和公司发展部工作，该公司现在是生物科技公司Roche Group的成员，最近一职是高级经理。加入Genentech前，他是Stanford University的毕业生，获得免疫学的医学博士和哲学博士学位。他获得Rice University生物化学和计算机科学的学士学位。除Seattle Genetics外，他也是上市生物科技公司Intercept Pharmaceuticals, Inc.的董事。此前，他曾任Versartis, Inc.、Barrier Therapeutics, Inc.、Eyetech Pharmaceuticals, Inc.以及Synageva Biopharma Corp.的董事，这些公司在其任职期间都是上市生物科技公司。他还曾担任国外上市生物科技公司Amarin Corporation plc的董事。
- Srinivas Akkaraju,has served as a member of Alumis Inc. board of directors since March 2024. Dr. Akkaraju is a founder and managing member of Samsara BioCapital, a venture capital firm, a position he has held since March 2017. From April 2013 to February 2016, Dr. Akkaraju served as a general partner of Sofinnova Ventures, a venture capital firm. From January 2009 to April 2013, Dr. Akkaraju served as managing director of New Leaf Venture Partners, a venture capital firm. Dr. Akkaraju presently serves on the board of directors of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., and Syros Pharmaceuticals, Inc., and numerous private biopharmaceutical companies. During the past five years, he served as a director of Chinook Therapeutics, Inc., Jiya Acquisition Corp., Aravive, Inc. (formerly Versartis, Inc.), Intercept Pharmaceuticals, Inc., Principia Biopharma Inc., and Seattle Genetics, Inc. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University.
- David Hallal
-
David Hallal，自合并完成后一直担任Kalaris Therapeutics，Inc.董事会主席。在合并完成之前，Hallal先生于2021年5月至合并完成前担任Kalaris Therapeutics，Inc.执行董事长，此前曾于2018年9月至2021年5月担任Kalaris Therapeutics，Inc.首席执行官兼董事长。Hallal先生自2025年4月起担任上市公司Scholar Rock Holding公司的首席执行官，并自2017年7月起担任Scholar Rock Holding公司的董事会主席。Hallal先生担任ElevateBio的执行董事长，自2017年12月起，他担任ElevateBio的董事长、首席执行官和联合创始人，该公司是他与他人共同创立的。Hallal先生还担任iTeos Therapeutics SA（一家上市公司）的董事会主席。Halal先生还曾于2018年2月至2025年5月担任上市公司Seer Biosciences，Inc.的董事会成员。在此之前，从2006年6月至2016年12月，Hallal先生在亚力兄制药公司（Alexion Pharmaceuticals，Inc.）或Alexion（一家上市公司）担任越来越重要的高管职务，最近担任首席执行官和董事会成员。在担任首席执行官之前，Hallal先生曾在Alexion担任首席运营官和董事以及首席商务官和商业运营主管。在加入Alexion之前，2004年至2006年，Hallal先生担任OSI Eyetech，Inc.的销售副总裁。2002年至2004年，Hallal先生在上市公司Biogen Inc.担任销售主管。从1992年到2002年，Hallal先生在上市公司安进公司担任过各种领导职务。从1988年到1992年，Hallal先生在Upjohn公司开始了他的制药生涯，担任销售代表。Hallal先生拥有新罕布什尔大学心理学学士学位。
David Hallal,has served as a member of board of directors since February 2018 and as Lead Independent Director from September 2020 to August 2024. Mr. Hallal has served as Chief Executive Officer of ElevateBio LLC, a biotechnology company he co-founded, since December 2017. Mr. Hallal had served as Chief Executive Officer of AlloVir, Inc., a late clinical-stage cell therapy company from September 2018 to March 2021. Prior to that, from June 2006 to December 2016, Mr. Hallal served in executive roles of increasing responsibility at Alexion Pharmaceuticals, Inc., a pharmaceutical company, most recently serving as Chief Executive Officer from April 2015 to December 2016, Chief Operating Officer from September 2014 to April 2015 and Chief Commercial Officer, Head of Commercial Operations from July 2006 to September 2014, as well as a member of the Board of Directors from September 2014 to December 2016. Mr. Hallal currently serves as Chairman of the board at AlloVir, ElevateBio, Scholar Rock Holding Corp. and iTeos Therapeutics S.A. He holds a B.A. in Psychology from the University of New Hampshire. - David Hallal，自合并完成后一直担任Kalaris Therapeutics，Inc.董事会主席。在合并完成之前，Hallal先生于2021年5月至合并完成前担任Kalaris Therapeutics，Inc.执行董事长，此前曾于2018年9月至2021年5月担任Kalaris Therapeutics，Inc.首席执行官兼董事长。Hallal先生自2025年4月起担任上市公司Scholar Rock Holding公司的首席执行官，并自2017年7月起担任Scholar Rock Holding公司的董事会主席。Hallal先生担任ElevateBio的执行董事长，自2017年12月起，他担任ElevateBio的董事长、首席执行官和联合创始人，该公司是他与他人共同创立的。Hallal先生还担任iTeos Therapeutics SA（一家上市公司）的董事会主席。Halal先生还曾于2018年2月至2025年5月担任上市公司Seer Biosciences，Inc.的董事会成员。在此之前，从2006年6月至2016年12月，Hallal先生在亚力兄制药公司（Alexion Pharmaceuticals，Inc.）或Alexion（一家上市公司）担任越来越重要的高管职务，最近担任首席执行官和董事会成员。在担任首席执行官之前，Hallal先生曾在Alexion担任首席运营官和董事以及首席商务官和商业运营主管。在加入Alexion之前，2004年至2006年，Hallal先生担任OSI Eyetech，Inc.的销售副总裁。2002年至2004年，Hallal先生在上市公司Biogen Inc.担任销售主管。从1992年到2002年，Hallal先生在上市公司安进公司担任过各种领导职务。从1988年到1992年，Hallal先生在Upjohn公司开始了他的制药生涯，担任销售代表。Hallal先生拥有新罕布什尔大学心理学学士学位。
- David Hallal,has served as a member of board of directors since February 2018 and as Lead Independent Director from September 2020 to August 2024. Mr. Hallal has served as Chief Executive Officer of ElevateBio LLC, a biotechnology company he co-founded, since December 2017. Mr. Hallal had served as Chief Executive Officer of AlloVir, Inc., a late clinical-stage cell therapy company from September 2018 to March 2021. Prior to that, from June 2006 to December 2016, Mr. Hallal served in executive roles of increasing responsibility at Alexion Pharmaceuticals, Inc., a pharmaceutical company, most recently serving as Chief Executive Officer from April 2015 to December 2016, Chief Operating Officer from September 2014 to April 2015 and Chief Commercial Officer, Head of Commercial Operations from July 2006 to September 2014, as well as a member of the Board of Directors from September 2014 to December 2016. Mr. Hallal currently serves as Chairman of the board at AlloVir, ElevateBio, Scholar Rock Holding Corp. and iTeos Therapeutics S.A. He holds a B.A. in Psychology from the University of New Hampshire.
- Amir Nashat
-
Amir Nashat, Sc.D.，2008年2月成为Scholar Rock Holding Corporation的董事会成员。自2009年以来，他是Polaris Venture Partners公司（一个风险投资公司）一般合伙人，专注于生命科学投资。他目前是Receptos有限公司董事会和Fate Therapeutics公司董事会成员。他在麻省理工学院的化学工程完成了他的科学博士学位，在Langer博士的指导下辅修生物学。他持有加州大学，伯克利分校材料科学与机械工程硕士和博士学位。
Amir Nashat,has served as a member of Board since 2015. Dr. Nashat is an executive partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat currently represents Polaris on the board of directors of Morphic Holding, Inc., a biopharmaceutical company developing small molecule integrin therapeutics, where he has served since 2017. Dr. Nashat previously served as a member of the boards of directors of Scholar Rock Holding Corporation from 2012 to June 2024, of Fate Therapeutics, Inc., from 2007 to May 2020, of Selecta Biosciences, Inc., from 2008 to April 2020, and of Syros Pharmaceuticals, Inc., from 2016 to September 2022. Prior to joining Polaris, Dr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley. - Amir Nashat, Sc.D.，2008年2月成为Scholar Rock Holding Corporation的董事会成员。自2009年以来，他是Polaris Venture Partners公司（一个风险投资公司）一般合伙人，专注于生命科学投资。他目前是Receptos有限公司董事会和Fate Therapeutics公司董事会成员。他在麻省理工学院的化学工程完成了他的科学博士学位，在Langer博士的指导下辅修生物学。他持有加州大学，伯克利分校材料科学与机械工程硕士和博士学位。
- Amir Nashat,has served as a member of Board since 2015. Dr. Nashat is an executive partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat currently represents Polaris on the board of directors of Morphic Holding, Inc., a biopharmaceutical company developing small molecule integrin therapeutics, where he has served since 2017. Dr. Nashat previously served as a member of the boards of directors of Scholar Rock Holding Corporation from 2012 to June 2024, of Fate Therapeutics, Inc., from 2007 to May 2020, of Selecta Biosciences, Inc., from 2008 to April 2020, and of Syros Pharmaceuticals, Inc., from 2016 to September 2022. Prior to joining Polaris, Dr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.
高管简历
中英对照 | 中文 | 英文- Jay Backstrom
Jay Backstrom，自2022年9月起担任董事兼Scholar Rock Holding Corporation总裁兼首席执行官。在加入Scholar Rock之前，从2019年12月到2021年12月，Backstrom博士在Acceleron制药担任研发执行副总裁，该公司于2021年被默沙东收购。Backstrom博士此前于2016年4月至2019年12月担任新基医药公司的首席医疗官，此前曾于2008年3月至2016年3月在Celgene担任其他职务。2002年至2008年，Backstrom博士在Pharmion Corporation工作，先是担任北美医疗事务和安全主管，后来担任全球医疗和安全副总裁。在加入Pharmion之前，Backstrom博士还曾在Quintiles Corporation、Hoechst Marion Roussel，Inc.和Marion Merrell Dow，Inc.任职。Backstrom博士目前是LAVA Therapeutics N.V.、Be BioPharma，Inc.和Disc Medicine，Inc.（他将于2023年6月卸任）的董事会成员。Backstrom博士在天普大学医学院获得医学博士学位，并拥有圣路易斯大学公共卫生学院的硕士学位。
Jay Backstrom,has served as a director and Scholar Rock Holding Corporation President and Chief Executive Officer since September 2022. Prior to joining Scholar Rock, from December 2019 to December 2021, Dr. Backstrom served as Executive Vice President, Research and Development at Acceleron Pharma, which was acquired by Merck in 2021. Dr. Backstrom previously served as Chief Medical Officer of Celgene Corporation from April 2016 to December 2019, having served in other roles at Celgene from March 2008 to March 2016. From 2002 to 2008 Dr. Backstrom worked at Pharmion Corporation, serving first as the Head of North American Medical Affairs and Safety and later as Vice President, Global Medical and Safety. Prior to Pharmion, Dr. Backstrom also held roles at Quintiles Corporation, Hoechst Marion Roussel, Inc. and Marion Merrell Dow, Inc. Dr. Backstrom currently sits on the board of directors of Lava Therapeutics N.V., Be BioPharma, Inc., and Disc Medicine, Inc. (which he will be stepping down from in June 2023). Dr. Backstrom earned his M.D. from Temple University School of Medicine, and holds an M.P.H. From St. Louis University School of Public Health.- Jay Backstrom，自2022年9月起担任董事兼Scholar Rock Holding Corporation总裁兼首席执行官。在加入Scholar Rock之前，从2019年12月到2021年12月，Backstrom博士在Acceleron制药担任研发执行副总裁，该公司于2021年被默沙东收购。Backstrom博士此前于2016年4月至2019年12月担任新基医药公司的首席医疗官，此前曾于2008年3月至2016年3月在Celgene担任其他职务。2002年至2008年，Backstrom博士在Pharmion Corporation工作，先是担任北美医疗事务和安全主管，后来担任全球医疗和安全副总裁。在加入Pharmion之前，Backstrom博士还曾在Quintiles Corporation、Hoechst Marion Roussel，Inc.和Marion Merrell Dow，Inc.任职。Backstrom博士目前是LAVA Therapeutics N.V.、Be BioPharma，Inc.和Disc Medicine，Inc.（他将于2023年6月卸任）的董事会成员。Backstrom博士在天普大学医学院获得医学博士学位，并拥有圣路易斯大学公共卫生学院的硕士学位。
- Jay Backstrom,has served as a director and Scholar Rock Holding Corporation President and Chief Executive Officer since September 2022. Prior to joining Scholar Rock, from December 2019 to December 2021, Dr. Backstrom served as Executive Vice President, Research and Development at Acceleron Pharma, which was acquired by Merck in 2021. Dr. Backstrom previously served as Chief Medical Officer of Celgene Corporation from April 2016 to December 2019, having served in other roles at Celgene from March 2008 to March 2016. From 2002 to 2008 Dr. Backstrom worked at Pharmion Corporation, serving first as the Head of North American Medical Affairs and Safety and later as Vice President, Global Medical and Safety. Prior to Pharmion, Dr. Backstrom also held roles at Quintiles Corporation, Hoechst Marion Roussel, Inc. and Marion Merrell Dow, Inc. Dr. Backstrom currently sits on the board of directors of Lava Therapeutics N.V., Be BioPharma, Inc., and Disc Medicine, Inc. (which he will be stepping down from in June 2023). Dr. Backstrom earned his M.D. from Temple University School of Medicine, and holds an M.P.H. From St. Louis University School of Public Health.
- Junlin Ho
何俊麟，自2021年2月起担任Scholar Rock Holding Corporation总法律顾问兼公司秘书。何女士于2018年3月加入Scholar Rock，担任Scholar Rock Holding Corporation副总裁、企业法律主管，并于2020年3月至2021年1月担任Scholar Rock Holding Corporation高级副总裁、法律和公司秘书主管。在加入Scholar Rock之前，何女士于2013年至2018年在Foundation Medicine任职，担任越来越重要的职务，最近担任副总法律顾问。她还在2013年担任Ziopharm Oncology的副总法律顾问。在此之前，何女士是Ropes & Gray LLP生命科学业务的公司律师。何女士获得了麻省理工学院的学士学位和芝加哥大学法学院的法学博士学位。
Junlin Ho,has served as Scholar Rock Holding Corporation General Counsel & Corporate Secretary since February 2021. Ms. Ho joined Scholar Rock in March 2018 as Scholar Rock Holding Corporation VP, Head of Corporate Legal and served as Scholar Rock Holding Corporation SVP, Head of Legal & Corporate Secretary from March 2020 to January 2021. Prior to Scholar Rock, Ms. Ho worked at Foundation Medicine from 2013 to 2018 in roles of increasing responsibility, most recently as Associate General Counsel. She also served as Associate General Counsel at Ziopharm Oncology in 2013. Prior to that, Ms. Ho was a corporate attorney in the life sciences practice of Ropes & Gray LLP. Ms. Ho received her B.S. from the Massachusetts Institute of Technology and J.D. from the University of Chicago Law School.- 何俊麟，自2021年2月起担任Scholar Rock Holding Corporation总法律顾问兼公司秘书。何女士于2018年3月加入Scholar Rock，担任Scholar Rock Holding Corporation副总裁、企业法律主管，并于2020年3月至2021年1月担任Scholar Rock Holding Corporation高级副总裁、法律和公司秘书主管。在加入Scholar Rock之前，何女士于2013年至2018年在Foundation Medicine任职，担任越来越重要的职务，最近担任副总法律顾问。她还在2013年担任Ziopharm Oncology的副总法律顾问。在此之前，何女士是Ropes & Gray LLP生命科学业务的公司律师。何女士获得了麻省理工学院的学士学位和芝加哥大学法学院的法学博士学位。
- Junlin Ho,has served as Scholar Rock Holding Corporation General Counsel & Corporate Secretary since February 2021. Ms. Ho joined Scholar Rock in March 2018 as Scholar Rock Holding Corporation VP, Head of Corporate Legal and served as Scholar Rock Holding Corporation SVP, Head of Legal & Corporate Secretary from March 2020 to January 2021. Prior to Scholar Rock, Ms. Ho worked at Foundation Medicine from 2013 to 2018 in roles of increasing responsibility, most recently as Associate General Counsel. She also served as Associate General Counsel at Ziopharm Oncology in 2013. Prior to that, Ms. Ho was a corporate attorney in the life sciences practice of Ropes & Gray LLP. Ms. Ho received her B.S. from the Massachusetts Institute of Technology and J.D. from the University of Chicago Law School.
- Jing Marantz
Jing Marantz，自2022年11月起担任Scholar Rock Holding Corporation首席医疗官。在2022年1月至2022年8月加入Scholar Rock Holding Corporation之前，Marantz博士于2020年10月至2022年1月期间担任Krystal Biotech, Inc.首席商务官，她曾担任默沙东于2021年被Merck收购的Acceleron制药 Inc.的医疗事务高级副总裁。2018年6月至2020年9月，她担任阿尔尼拉姆制药医疗事务高级副总裁，在此之前，2016年8月至2018年6月，担任亚力兄制药医疗事务副总裁。她曾是Strategic Decisions Group的管理顾问，在Dana-Farber癌症研究所获得博士后研究金后，曾短暂附属于麻省总医院。Marantz博士目前还担任Arcturus医疗公司的董事会成员。她曾在同济医学院接受医学培训，在南卡罗来纳医科大学获得生物化学和分子生物学博士学位，在加州大学伯克利分校获得MBA学位。
Jing Marantz,has served as Scholar Rock Holding Corporation Chief Medical Officer since November 2022. Prior to joining Scholar Rock Holding Corporation from January 2022 to August 2022, Dr. Marantz served as Chief Business Officer for Krystal Biotech, Inc. From October 2020 to January 2022, she served as Senior Vice President of Medical Affairs of Acceleron Pharma Inc. acquired by Merck in 2021. From June 2018 to September 2020, she served as Senior Vice President of Medical Affairs at Alnylam Pharmaceuticals, and prior to that, from August 2016 to June 2018, she served as Vice President of Medical Affairs at Alexion Pharmaceuticals. She was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. Dr. Marantz also currently sits on the board of directors of Arcturus Therapeutics, Inc. She received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.- Jing Marantz，自2022年11月起担任Scholar Rock Holding Corporation首席医疗官。在2022年1月至2022年8月加入Scholar Rock Holding Corporation之前，Marantz博士于2020年10月至2022年1月期间担任Krystal Biotech, Inc.首席商务官，她曾担任默沙东于2021年被Merck收购的Acceleron制药 Inc.的医疗事务高级副总裁。2018年6月至2020年9月，她担任阿尔尼拉姆制药医疗事务高级副总裁，在此之前，2016年8月至2018年6月，担任亚力兄制药医疗事务副总裁。她曾是Strategic Decisions Group的管理顾问，在Dana-Farber癌症研究所获得博士后研究金后，曾短暂附属于麻省总医院。Marantz博士目前还担任Arcturus医疗公司的董事会成员。她曾在同济医学院接受医学培训，在南卡罗来纳医科大学获得生物化学和分子生物学博士学位，在加州大学伯克利分校获得MBA学位。
- Jing Marantz,has served as Scholar Rock Holding Corporation Chief Medical Officer since November 2022. Prior to joining Scholar Rock Holding Corporation from January 2022 to August 2022, Dr. Marantz served as Chief Business Officer for Krystal Biotech, Inc. From October 2020 to January 2022, she served as Senior Vice President of Medical Affairs of Acceleron Pharma Inc. acquired by Merck in 2021. From June 2018 to September 2020, she served as Senior Vice President of Medical Affairs at Alnylam Pharmaceuticals, and prior to that, from August 2016 to June 2018, she served as Vice President of Medical Affairs at Alexion Pharmaceuticals. She was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. Dr. Marantz also currently sits on the board of directors of Arcturus Therapeutics, Inc. She received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.
- Edward H. Myles
Edward H. Myles，自2022年1月起担任Scholar Rock Holding Corporation首席运营官兼首席财务官，在此之前，自2020年7月起担任Scholar Rock Holding Corporation首席财务官和业务运营主管。Myles先生于2018年11月至2020年7月担任Scholar Rock Holding Corporation董事会成员。在加入Scholar Rock之前，Myles先生于2020年1月至2020年7月期间担任Amag制药制药公司（“AMAG”）的首席运营官和首席财务官。2016年4月至2020年1月任AMAG执行副总裁兼首席财务官。在加入AMAG之前，2013年6月至2016年4月，他在Ocata Therapeutics公司（“Ocata”）担任首席财务官和首席运营官，直到该公司被Astellas Pharma，Inc.收购。在Ocata之前，Myles先生于2008年11月至2013年6月在PrimeraDx，Inc.担任首席财务官和运营副总裁。Myles先生在其职业生涯的早期曾担任SG 高宏集团证券公司医疗保健投资银行组的助理，并于1993年至1997年期间担任Coopers & Lybrand LLP审计实务的高级助理。Myles先生拥有华盛顿大学John M. 欧林商学院工商管理硕士学位和哈特福德大学工商管理理学学士学位。
Edward H. Myles,has served as Scholar Rock Holding Corporation Chief Operating Officer and Chief Financial Officer since January 2022 and prior to that, as Scholar Rock Holding Corporation Chief Financial Officer and Head of Business Operations since July 2020. Mr. Myles served as a member of Scholar Rock Holding Corporation board from November 2018 to July 2020. Prior to joining Scholar Rock, Mr. Myles served as Chief Operating Officer and Chief Financial Officer of AMAG Pharmaceuticals, Inc. ("AMAG") from January 2020 to July 2020. He served as Executive Vice President and Chief Financial Officer of AMAG from April 2016 to January 2020. Prior to joining AMAG, from June 2013 to April 2016, he served as Chief Financial Officer and Chief Operating Officer at Ocata Therapeutics, Inc. ("Ocata") until it was acquired by Astellas Pharma, Inc. Prior to Ocata, Mr. Myles was Chief Financial Officer and Vice President of Operations at PrimeraDx, Inc. from November 2008 to June 2013. Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation, and was a senior associate in the audit practice of Coopers & Lybrand LLP from 1993 to 1997. Mr. Myles holds a Master of Business Administration from John M. Olin School of Business at Washington University and Bachelor of Science in Business Administration from the University of Hartford.- Edward H. Myles，自2022年1月起担任Scholar Rock Holding Corporation首席运营官兼首席财务官，在此之前，自2020年7月起担任Scholar Rock Holding Corporation首席财务官和业务运营主管。Myles先生于2018年11月至2020年7月担任Scholar Rock Holding Corporation董事会成员。在加入Scholar Rock之前，Myles先生于2020年1月至2020年7月期间担任Amag制药制药公司（“AMAG”）的首席运营官和首席财务官。2016年4月至2020年1月任AMAG执行副总裁兼首席财务官。在加入AMAG之前，2013年6月至2016年4月，他在Ocata Therapeutics公司（“Ocata”）担任首席财务官和首席运营官，直到该公司被Astellas Pharma，Inc.收购。在Ocata之前，Myles先生于2008年11月至2013年6月在PrimeraDx，Inc.担任首席财务官和运营副总裁。Myles先生在其职业生涯的早期曾担任SG 高宏集团证券公司医疗保健投资银行组的助理，并于1993年至1997年期间担任Coopers & Lybrand LLP审计实务的高级助理。Myles先生拥有华盛顿大学John M. 欧林商学院工商管理硕士学位和哈特福德大学工商管理理学学士学位。
- Edward H. Myles,has served as Scholar Rock Holding Corporation Chief Operating Officer and Chief Financial Officer since January 2022 and prior to that, as Scholar Rock Holding Corporation Chief Financial Officer and Head of Business Operations since July 2020. Mr. Myles served as a member of Scholar Rock Holding Corporation board from November 2018 to July 2020. Prior to joining Scholar Rock, Mr. Myles served as Chief Operating Officer and Chief Financial Officer of AMAG Pharmaceuticals, Inc. ("AMAG") from January 2020 to July 2020. He served as Executive Vice President and Chief Financial Officer of AMAG from April 2016 to January 2020. Prior to joining AMAG, from June 2013 to April 2016, he served as Chief Financial Officer and Chief Operating Officer at Ocata Therapeutics, Inc. ("Ocata") until it was acquired by Astellas Pharma, Inc. Prior to Ocata, Mr. Myles was Chief Financial Officer and Vice President of Operations at PrimeraDx, Inc. from November 2008 to June 2013. Earlier in his career, Mr. Myles was an associate in the healthcare investment banking group at SG Cowen Securities Corporation, and was a senior associate in the audit practice of Coopers & Lybrand LLP from 1993 to 1997. Mr. Myles holds a Master of Business Administration from John M. Olin School of Business at Washington University and Bachelor of Science in Business Administration from the University of Hartford.
- Caryn Parlavecchio
Caryn Parlavecchio，自2021年8月起担任Scholar Rock Holding Corporation首席人力资源官。在加入Scholar Rock Holding Corporation之前，她最近于2020年8月至2021年7月担任圣名医疗中心副总裁兼首席人力资源官。从2001年到2020年7月，她在诺华制药担任过多个人力资源领导职务，包括副总裁兼全球人力资源主管、肿瘤学和制药发展、副总裁兼国家人力资源主管，以及北美人力资源服务副总裁。她获得了咨询心理学硕士学位和英语学士学位，均来自Seton Hall大学。
Caryn Parlavecchio,has served as Scholar Rock Holding Corporation Chief Human Resources Officer since August 2021. Prior to joining Scholar Rock Holding Corporation , she most recently served as Vice President and Chief Human Resources Officer at Holy Name Medical Center from August 2020 to July 2021. From 2001 to July 2020, she held various human resource leadership positions at Novartis Pharmaceuticals, including Vice President and Global HR Head, Oncology & Pharma Development, Vice President and Country HR Head, and Vice President, Human Resources Services, North America. She received a M.A. in Counseling Psychology and a B.A. in English, both from Seton Hall University.- Caryn Parlavecchio，自2021年8月起担任Scholar Rock Holding Corporation首席人力资源官。在加入Scholar Rock Holding Corporation之前，她最近于2020年8月至2021年7月担任圣名医疗中心副总裁兼首席人力资源官。从2001年到2020年7月，她在诺华制药担任过多个人力资源领导职务，包括副总裁兼全球人力资源主管、肿瘤学和制药发展、副总裁兼国家人力资源主管，以及北美人力资源服务副总裁。她获得了咨询心理学硕士学位和英语学士学位，均来自Seton Hall大学。
- Caryn Parlavecchio,has served as Scholar Rock Holding Corporation Chief Human Resources Officer since August 2021. Prior to joining Scholar Rock Holding Corporation , she most recently served as Vice President and Chief Human Resources Officer at Holy Name Medical Center from August 2020 to July 2021. From 2001 to July 2020, she held various human resource leadership positions at Novartis Pharmaceuticals, including Vice President and Global HR Head, Oncology & Pharma Development, Vice President and Country HR Head, and Vice President, Human Resources Services, North America. She received a M.A. in Counseling Psychology and a B.A. in English, both from Seton Hall University.
- Mo Qatanani
Mo Qatanani，自2022年9月起担任Scholar Rock Holding Corporation高级副总裁，负责研究。在加入Scholar Rock Holding Corporation之前，他于2018年2月至2021年9月担任Dyne Therapeutics，Inc.副总裁兼研究主管。在加入达因之前，2009年至2014年，他曾在亚力兄制药（2015年至2018年）、Synageva BioPharma（2014年至2015年）、默沙东（2009年至2014年）担任越来越负责的研究职位。他拥有贝勒医学院分子和人类遗传学博士学位，并在宾夕法尼亚大学医学院完成博士后研究。他拥有贝鲁特美国大学生物学学士和理学硕士学位。
Mo Qatanani,has served as Scholar Rock Holding Corporation Senior Vice President, Research since September 2022. Prior to joining Scholar Rock Holding Corporation , he was Vice President, and Head of Research at Dyne Therapeutics, Inc. from February 2018 to September 2021. Prior to Dyne, from 2009 to 2014, he held research positions of increasing responsibility at Alexion Pharmaceuticals (2015 to 2018), Synageva BioPharma (2014 to 2015), and Merck (2009 to 2014). He holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.- Mo Qatanani，自2022年9月起担任Scholar Rock Holding Corporation高级副总裁，负责研究。在加入Scholar Rock Holding Corporation之前，他于2018年2月至2021年9月担任Dyne Therapeutics，Inc.副总裁兼研究主管。在加入达因之前，2009年至2014年，他曾在亚力兄制药（2015年至2018年）、Synageva BioPharma（2014年至2015年）、默沙东（2009年至2014年）担任越来越负责的研究职位。他拥有贝勒医学院分子和人类遗传学博士学位，并在宾夕法尼亚大学医学院完成博士后研究。他拥有贝鲁特美国大学生物学学士和理学硕士学位。
- Mo Qatanani,has served as Scholar Rock Holding Corporation Senior Vice President, Research since September 2022. Prior to joining Scholar Rock Holding Corporation , he was Vice President, and Head of Research at Dyne Therapeutics, Inc. from February 2018 to September 2021. Prior to Dyne, from 2009 to 2014, he held research positions of increasing responsibility at Alexion Pharmaceuticals (2015 to 2018), Synageva BioPharma (2014 to 2015), and Merck (2009 to 2014). He holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed a post-doctoral fellowship at the University of Pennsylvania School of Medicine. He has a B.Sc. and a M.Sc. in Biology from the American University of Beirut.
- Tracey Sacco
Tracey Sacco，自2023年2月起担任Scholar Rock Holding Corporation首席商务官。在加入Scholar Rock Holding Corporation之前，她曾任职于Nemetz集团，于2021年9月至2023年1月期间担任顾问。2012年6月至2021年8月，她在Acceleron Pharma Inc.（已被默沙东收购）担任越来越重要的职务，最近担任全球战略营销高级副总裁。在2005年至2012年加入Acceleron之前，她曾在赛诺菲（原Genzyme）、Oscient Pharmaceuticals、辉瑞担任商业战略和业务发展职务。她拥有纽约大学斯特恩商学院的工商管理硕士学位和波士顿学院的经济学和社会学学士学位。
Tracey Sacco,has served as Scholar Rock Holding Corporation Chief Commercial Officer since February 2023. Prior to joining Scholar Rock Holding Corporation , she worked at The Nemetz Group, where she served as a consultant from September 2021 to January 2023. From June 2012 to August 2021, she held positions of increasing responsibility at Acceleron Pharma Inc. (acquired by Merck), most recently serving as Senior Vice President, Global Strategic Marketing. Prior to Acceleron from 2005 to 2012, she held roles in commercial strategy and business development at Sanofi (formerly Genzyme), Oscient Pharmaceuticals, and Pfizer. She holds an M.B.A. from NYU Stern School of Business and a B.A. in Economics and Sociology from Boston College.- Tracey Sacco，自2023年2月起担任Scholar Rock Holding Corporation首席商务官。在加入Scholar Rock Holding Corporation之前，她曾任职于Nemetz集团，于2021年9月至2023年1月期间担任顾问。2012年6月至2021年8月，她在Acceleron Pharma Inc.（已被默沙东收购）担任越来越重要的职务，最近担任全球战略营销高级副总裁。在2005年至2012年加入Acceleron之前，她曾在赛诺菲（原Genzyme）、Oscient Pharmaceuticals、辉瑞担任商业战略和业务发展职务。她拥有纽约大学斯特恩商学院的工商管理硕士学位和波士顿学院的经济学和社会学学士学位。
- Tracey Sacco,has served as Scholar Rock Holding Corporation Chief Commercial Officer since February 2023. Prior to joining Scholar Rock Holding Corporation , she worked at The Nemetz Group, where she served as a consultant from September 2021 to January 2023. From June 2012 to August 2021, she held positions of increasing responsibility at Acceleron Pharma Inc. (acquired by Merck), most recently serving as Senior Vice President, Global Strategic Marketing. Prior to Acceleron from 2005 to 2012, she held roles in commercial strategy and business development at Sanofi (formerly Genzyme), Oscient Pharmaceuticals, and Pfizer. She holds an M.B.A. from NYU Stern School of Business and a B.A. in Economics and Sociology from Boston College.